Our allogeneic platform offers broader and faster treatment with cell therapies where speed and cost are paramount for patient access and where our proprietary potent cell format offers sufficient persistence.
Faster from diagnosis to treatment
Starting material from healthy donors
Simpler manufacturing process
1 batch ~ 1000 patients
Large treatment stock